Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Brivaracetam tablets Clear all

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 1 Month and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Hawthorne, New York • Durham, North Carolina

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam Film-coated tablet, Brivaracetam oral solution; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam Film-coated tablet, Brivaracetam oral solution; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 26 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 16 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more

Conditions: Epilepsy
Interventions: Brivaracetam (BRV); Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 15
States / cities: Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more

Conditions: Epilepsy
Interventions: Brivaracetam (ucb 34714); Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years and older
Enrollment: 853 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Gainesville, Florida • Charlottesville, Virginia

Conditions: Unverricht-Lundborg Disease
Interventions: Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • New York, New York + 1 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more

Conditions: Epilepsy
Interventions: Brivaracetam, levetiracetam, lorazepam, placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Nonconvulsive Electrographic Seizures
Interventions: Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution, Phenytoin oral tablets; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Lexington, Kentucky • Jackson, Mississippi

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 26
States / cities: Phoenix, Arizona • Fresno, California • Pasadena, California + 23 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 43
States / cities: Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB PHARMA Inc. (US); Industry
Eligibility: 16 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Conditions: Healthy Volunteers
Interventions: [11C]UCB-J, Brivaracetam, Levetiracetam; Radiation · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Fresno, California • Pasadena, California + 22 more

Search by objective public record fields.

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam